Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes

Alberto Grossi, Pellegrino Musto, Valeria Santini, Francesca Balestri, Alberto Fabbri, Antonietta Falcone, Grazia Sanpaolo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12 (16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count ≤100×109/L had a complete response, as did 3/9 with a neutrophil count 9/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

Original languageEnglish
Pages (from-to)322-323
Number of pages2
JournalHaematologica
Volume87
Issue number3
Publication statusPublished - 2002

Fingerprint

Amifostine
Myelodysplastic Syndromes
Erythropoietin
Platelet Count
Neutrophils
Therapeutics

Keywords

  • Amifostine
  • MDS
  • Myelodysplastic syndromes
  • RHuEPO

ASJC Scopus subject areas

  • Hematology

Cite this

Grossi, A., Musto, P., Santini, V., Balestri, F., Fabbri, A., Falcone, A., & Sanpaolo, G. (2002). Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica, 87(3), 322-323.

Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. / Grossi, Alberto; Musto, Pellegrino; Santini, Valeria; Balestri, Francesca; Fabbri, Alberto; Falcone, Antonietta; Sanpaolo, Grazia.

In: Haematologica, Vol. 87, No. 3, 2002, p. 322-323.

Research output: Contribution to journalArticle

Grossi, A, Musto, P, Santini, V, Balestri, F, Fabbri, A, Falcone, A & Sanpaolo, G 2002, 'Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes', Haematologica, vol. 87, no. 3, pp. 322-323.
Grossi, Alberto ; Musto, Pellegrino ; Santini, Valeria ; Balestri, Francesca ; Fabbri, Alberto ; Falcone, Antonietta ; Sanpaolo, Grazia. / Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. In: Haematologica. 2002 ; Vol. 87, No. 3. pp. 322-323.
@article{2d1f7582b7734efebc56dc51773824bd,
title = "Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes",
abstract = "Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12 (16.6{\%}) and a partial response in 4/12 (33.3{\%}). Two of 8 patients with a platelet count ≤100×109/L had a complete response, as did 3/9 with a neutrophil count 9/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.",
keywords = "Amifostine, MDS, Myelodysplastic syndromes, RHuEPO",
author = "Alberto Grossi and Pellegrino Musto and Valeria Santini and Francesca Balestri and Alberto Fabbri and Antonietta Falcone and Grazia Sanpaolo",
year = "2002",
language = "English",
volume = "87",
pages = "322--323",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes

AU - Grossi, Alberto

AU - Musto, Pellegrino

AU - Santini, Valeria

AU - Balestri, Francesca

AU - Fabbri, Alberto

AU - Falcone, Antonietta

AU - Sanpaolo, Grazia

PY - 2002

Y1 - 2002

N2 - Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12 (16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count ≤100×109/L had a complete response, as did 3/9 with a neutrophil count 9/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

AB - Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12 (16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count ≤100×109/L had a complete response, as did 3/9 with a neutrophil count 9/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

KW - Amifostine

KW - MDS

KW - Myelodysplastic syndromes

KW - RHuEPO

UR - http://www.scopus.com/inward/record.url?scp=0036194073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036194073&partnerID=8YFLogxK

M3 - Article

C2 - 11869946

AN - SCOPUS:0036194073

VL - 87

SP - 322

EP - 323

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -